Reaction
Papilloma Viral Infection reporting signals
As of the last recalculation, Papilloma Viral Infection appears in 1,628 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL AND ETHINYL ESTRADIOL (PRR 54.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Etonogestrel And Ethinyl Estradiol | 89 | 54.2 | 54.4 |
| Mycophenilic Acid | 43 | 27.2 | 27.3 |
| Mycophenolic Acid | 46 | 18.9 | 18.9 |
| Tacrolimus Ointment 0.1% | 162 | 18.4 | 18.4 |
| Tacrolimus Extended-Release Capsules | 162 | 18.3 | 18.3 |
| Mycophenolate Mofetil | 166 | 17.3 | 17.3 |
| Sirolimus | 18 | 17.3 | 17.3 |
| Mycophenolate Mofetil Hydrochloride | 166 | 17.3 | 17.3 |
| Tacrolimus | 172 | 15.6 | 15.6 |
| Copper | 50 | 15.3 | 15.3 |
| Everolimus Tablets | 19 | 14.6 | 14.7 |
| Basiliximab | 13 | 14.2 | 14.3 |
| Alemtuzumab | 21 | 14.1 | 14.1 |
| Bleomycin Sulfate | 11 | 13.7 | 13.7 |
| Fingolimod Hcl | 86 | 13.4 | 13.4 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 11.1 | 11.1 |
| Adalimumab-Fkjp | 38 | 10.7 | 10.7 |
| Adalimumab-Aaty | 38 | 10.5 | 10.5 |
| Adalimumab-Adaz | 39 | 9.7 | 9.7 |
| Ocrelizumab | 43 | 9.1 | 9.1 |
| Erlotinib Hydrochloride | 8 | 8.2 | 8.2 |
| Tofacitinib Citrate | 7 | 6.9 | 6.9 |
| Baricitinib | 5 | 6.6 | 6.7 |
| Erlotinib | 4 | 5.3 | 5.3 |
| Ofatumumab | 13 | 5.0 | 5.0 |
| Ustekinumab | 37 | 4.7 | 4.7 |
| Levonorgestrel | 60 | 3.9 | 3.9 |
| Natalizumab | 40 | 2.9 | 2.9 |
| Guselkumab | 6 | 2.1 | 2.1 |
| Etonogestrel | 8 | 2.1 | 2.1 |